ReviewBone research2026
Advances in heterogeneity and classification of osteoarthritis.
Review in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MSC-EVs in Cartilage Regeneration and Immunomodulation: Mechanisms and Therapeutic Prospects for Osteoarthritis, Rheumatoid Arthritis and Intervertebral Disc Degeneration.International journal of molecular sciences · 2026Review
- Experimental models of osteoarthritis: Advances, limitations and rational selection for translational research.Journal of orthopaedic translation · 2026Review
- NO-Responsive Oleanolic Acid Self-Assembled Micelles Co-Loaded with BAY 11-7082 for Synergistic Chondroprotection and Anti-Osteoarthritis Therapy.Bioengineering (Basel, Switzerland) · 2026Article
- Mammalian cell-derived extracellular vesicles remodel the immune-repair microenvironment in osteoarthritis: from pathological signal transmission to regenerative therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteoarthritis (OA) is a highly heterogeneous disease that exhibits distinct clinical manifestations and pathological mechanisms in different joints, patients, and even at different disease stages for the same patient. Genetic and pathophysiological factors contribute to the heterogeneity of OA in clinical manifestations, treatment responses, and prognosis of patients. Despite efforts in developing disease-modifying OA drugs and treatment technologies, no current approach can efficiently delay OA progression, and results from clinical research are inconsistent due to the mismatch between treatment mechanisms and heterogeneous patient subtypes. Researchers utilize clinical data to classify OA into different phenotypes based on etiological factors, clinical symptoms, and imaging features, as well as endotypes based on biomarkers, molecular mechanisms, metabolism profiles, and omics analyses, but there is still a lack of unified standards. Therefore, a comprehensive understanding of the heterogeneity and classification of OA is crucial for stratified and personalized treatment. In this Review, we discuss the heterogeneity of OA, with an emphasis on heterogeneity in treatment responses. We provide a structured analysis of current studies of OA classification, offering new perspectives for future OA research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.